Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity
Authors' conclusion
Treatment with rTMS produced a comparable reduction in BW to that observed with the GLP1-RA semaglutide (at the dose of 0.5 mg/week) and represents a promising intervention for the treatment of obesity and T2D.
Study context
- Population
- Patients with obesity and T2D; all received dietary advice on moderate caloric restriction (−300 kcal/day)
- Participants
- 40 / 37 / 30
- Exposure
- Repetitive transcranial magnetic stimulation (rTMS) vs semaglutide vs SGLT2i
- SGLT2in = 40
- Semaglutiden = 37
- rTMSn = 30
- Outcome
- Reduction in body weight
- Follow-up
- 1 year
Main finding
As reported in the abstract
Weight loss · 12 months
rTMS
−8.2
± 1.0 · kg
Semaglutide
−5.7
± 0.9 · kg
SGLT2i
−2.0
± 0.7 · kg
rTMS vs Semaglutide: not significantly different · SGLT2i vs Semaglutide: P = 0.01 · SGLT2i vs rTMS: P < 0.0001
Observational data: associations, not effects.
Further findings
Body weight trajectory · month 6 to month 12
- Weight regain with SGLT2i from month 6 to 12; progressive body weight (BW) decline with semaglutide and rTMS
Original publication
Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity. Obesity (Silver Spring). Published 26 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →